Biallelic germline and somatic mutations in malignant mesothelioma: Multiple mutations in transcription regulators including mSWI/SNF genes

International Journal of Cancer

Volumn 136, Issue 3, 2015, Pages 560-571

  Yoshikawa, Yoshie ^a   Sato, Ayuko ^a   Tsujimura, Tohru ^a   Otsuki, Taiichiro ^a   Fukuoka, Kazuya ^a   Hasegawa, Seiki ^a   Nakano, Takashi ^a   Hashimoto Tamaoki, Tomoko ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Malignant mesothelioma; MSWI SNF; Rare germline variant; Somatic mutation; Transcription regulator

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRG1 PROTEIN; BRM PROTEIN; HISTONE H3; NOTCH3 RECEPTOR; PROTEIN SWI; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR E2F7; TRANSCRIPTION FACTOR PAX7; TRANSCRIPTION FACTOR SNF; BAP1 PROTEIN, HUMAN; BRD1 PROTEIN, HUMAN; HISTONE; NONHISTONE PROTEIN; NUCLEAR PROTEIN; PBRM1 PROTEIN, HUMAN; SWI-SNF-B CHROMATIN-REMODELING COMPLEX; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ARID2 GENE; ARTICLE; CANCER CELL LINE; CHROMATIN ASSEMBLY AND DISASSEMBLY; COMPARATIVE GENOMIC HYBRIDIZATION; COMPLEX FORMATION; EXOME; GENE SEQUENCE; GENOTYPE; GERMLINE MUTATION; HETEROZYGOSITY; HISTONE ACETYLATION; HISTONE MODIFICATION; HOMOZYGOSITY; HUMAN; MALIGNANT MESOTHELIOMA; MICROARRAY ANALYSIS; MICROSATELLITE MARKER; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PBRM1 GENE; PROTEIN ANALYSIS; SETD2 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMARCA4 GENE; SMARCC1 GENE; SOMATIC MUTATION; TRANSCRIPTION REGULATION; TUMOR GENE; UNIPARENTAL DISOMY; WESTERN BLOTTING; ACETYLATION; GENETICS; LUNG TUMOR; MESOTHELIOMA; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ACETYLATION; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; GERM-LINE MUTATION; HISTONES; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84911002685     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29015     Document Type: Article

References (44)

1. Nojiri S, Gemba K, Aoe K, et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 2011;41: 32-9.
2. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3.
3. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-72.
4. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012;103:868-74.
5. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-5.
6. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-21.
7. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011;48: 856-9.
8. Carbone M, Korb Ferris L, Baumann F, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012;10:179.
9. Jensen DE, Proctor M, Marquis ST, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097-112.
10. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010;465:243-7.
11. Eletr ZM, Wilkinson KD. An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys 2011;60:3-11.
12. Sekido Y, Pass HI, Bader S, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227-31.
13. Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 2013;34: 1413-9.
14. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995;92:10854-8.
15. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int J Oncol 2011;39:1365-74.
16. Xue Y, Canman JC, Lee CS, et al. The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes. Proc Natl Acad Sci USA 2000;97:13015-20.
17. Charlop-Powers Z, Zeng L, Zhang Q, et al. Structural insights into selective histone H3 recognition by the human Polybromo bromodomain 2. Cell Res 2010;20:529-38.
18. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469:539-42.
19. Pawlowski R, Muhl SM, Sulser T, et al. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 2013;132: E11-7.
20. Guo G, Gui Y, Gao S, et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012;44:17-9.
21. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012;44:751-9.
22. Hakimi AA, Chen YB, Wren J, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013;63:848-54.
23. Kapur P, Pena-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013;14:159-67.
24. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11: 481-92.
25. Imbalzano AN, Kwon H, Green MR, et al. Facilitated binding of TATA-binding protein to nucleosomal DNA. Nature 1994;370:481-5.
26. Bultman S, Gebuhr T, Yee D, et al. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell 2000;6:1287-95.
27. Wang Z, Zhai W, Richardson JA, et al. Polybromo protein BAF180 functions in mammalian cardiac chamber maturation. Genes Dev 2004;18: 3106-16.
28. King HA, Trotter KW, Archer TK. Chromatin remodeling during glucocorticoid receptor regulated transactivation. Biochim Biophys Acta 2012; 1819:716-26.
29. Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 2013;45: 592-601.
30. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One 2013;8:e55119.
31. Cao XX, Mohuiddin I, Ece F, et al. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 2001;25: 562-8.
32. Crisanti MC, Wallace AF, Kapoor V, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009;8:2221-31.
33. Cingolani P, Platts A, Wang le L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 2012;6:80-92.
34. Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat 2013;34:E2393-402.
35. Dietrich W, Katz H, Lincoln SE, et al. A genetic map of the mouse suitable for typing intraspecific crosses. Genetics 1992;131:423-47.
36. Yu W, Chan-On W, Teo M, et al. First somatic mutation of E2F1 in a critical DNA binding residue discovered in well-differentiated papillary mesothelioma of the peritoneum. Genome Biol 2011;12:R96.
37. Sato Y, Yoshizato T, Shiraishi Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013;45:860-7.
38. Hyllus D, Stein C, Schnabel K, et al. PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev 2007;21: 3369-80.
39. Dowhan DH, Harrison MJ, Eriksson NA, et al. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocr Relat Cancer 2012;19:509-26.
40. Yoshimatsu M, Toyokawa G, Hayami S, et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 2011;128: 562-73.
41. Zhang Z, Jones A, Joo HY, et al. USP49 deubiquitinates histone H2B and regulates cotranscriptional pre-mRNA splicing. Genes Dev 2013;27: 1581-95.
42. Ye Y, Pringle LM, Lau AW, et al. TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappaB. Oncogene 2010;29:3619-29.
43. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-6.
44. Qin S, Jin L, Zhang J, et al. Recognition of unmodified histone H3 by the first PHD finger of bromodomain-PHD finger protein 2 provides insights into the regulation of histone acetyltransferases monocytic leukemic zinc-finger protein (MOZ) and MOZ-related factor (MORF). J Biol Chem 2011;286: 36944-55.